Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Underdilated VCX-TIPS vs EVL Plus NSBB for Secondary Prophylaxis of Variceal Bleeding in Cirrhosis
NCT07587671Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2026
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
Randomised, open-label trial in Liver cirrhosis (LC), Variceal bleeding and Portal Hypertension (PH) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Composite of All-Cause Death or Clinically Significant Upper Gastrointestinal Rebleeding at 1 year. Planned start Aug 2026; status: not yet recruiting.
02
Conditions
Liver cirrhosis (LC)Variceal bleedingPortal Hypertension (PH)
Beyond the preview
Go deeper on NCT07587671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07587671.